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Diagnosis, management, and future developments
of fibromuscular dysplasia
Jeffrey W. Olin, DO, and Brett A. Sealove, MD, New York, NY
Fibromuscular dysplasia (FMD) is a nonatherosclerotic noninflammatory vascular disease that primarily affects women
from age 20 to 60, but may also occur in infants and children, men, and the elderly. It most commonly affects the renal
and carotid arteries but has been observed in almost every artery in the body. FMD has been considered rare and thus is
often underdiagnosed and poorly understood by many health care providers. There are, however, data to suggest that
FMD is much more common than previously thought, perhaps affecting as many as 4% of adult women. When it affects
the renal arteries, the most common presentation is hypertension. When it affects the carotid or vertebral arteries, the
patient may present with transient ischemic attack or stroke, or dissection. An increasing number of patients are
asymptomatic and are only discovered incidentally when imaging is performed for some other reason or by the detection
of an asymptomatic bruit. FMD should be considered in the differential diagnosis of a young person with a cervical bruit;
a “swishing” sound in the ear(s); transient ischemic attack, stroke, or dissection of an artery; or in individuals aged <35
years with onset hypertension. Treatment consists of antiplatelet therapy for asymptomatic individuals and percutaneous
balloon angioplasty for patients with indications for intervention. Patients with aneurysms should be treated with a
covered stent or open surgical repair. Little new information has been published about FMD in the last 40 years. The
recently instituted International Registry for Fibromuscular Dysplasia will remedy that situation and provide observa-
tional data on a large numbers of patients with FMD. (J Vasc Surg 2011;53:826-36.)
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2Fibromuscular dysplasia (FMD) was first described in
1938 by Leadbetter and Burkland,1 and in the same year,
McCormack et al2 introduced the term when they reported
on three patients with renal artery stenosis and hyperten-
sion. FMD is a noninflammatory, nonatherosclerotic arte-
rial disease that most commonly affects the renal and ca-
rotid arteries but has been observed in almost every artery in
the body.3 Stenosis, aneurysm, dissection, and occlusion
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826ay occur, or the patient may be entirely asymptomatic.3,4
MD occurs most frequently in women aged between 20
nd 60, but may also be seen in men or older individuals.5
MDmay also be encountered in the pediatric population;
owever, the presentation and natural history of FMD in
nfants and children is quite different from adults and, thus,
ill not be discussed further in this review.6
Although most clinicians believe FMD is a rare disease,
he prevalence in the general population is not known.
here are three pieces of evidence that suggest that FMD is
ore common than previously thought:
. Potential renal donors. Cragg et al7 reviewed the
results of 1862 renal arteriograms in potential renal
donors and found FMD in 3.8%. A similar prevalence
was found in a more recent review.8 In a study by
Neymark et al,9 47 of 716 potential renal donors (6.6%)
demonstrated evidence of FMD on arteriography. It is
estimated that there are 151.5million women aged18
in the United States (http://www.census.gov/population/
www/socdemo/age/agebyage). If the data regarding
the prevalence of FMD in “normal” renal donors are
correct, then approximately 5.8 to 8.6million women in
the United States may have this disorder. Thus, this
condition is underdiagnosed and has been for 40
years.4,10
. Incidentally discovered on imaging. Since the advent of
better imaging techniques, FMDis frequently found inciden-
tallywhencomputed tomographyangiography (CTA),mag-
netic resonance angiography (MRA), duplex ultrasound
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Volume 53, Number 3 Olin and Sealove 827(DUS) imaging,orcatheter-basedangiogramsareperformed
for reasons unrelated to the FMD (Fig 1).
3. Incidentally discovered in the clinic. In patients pre-
senting to a vascular clinic for other reasons (ie, leg
swelling, leg ulcers, venous thrombosis), FMD may be
diagnosed after a carotid or abdominal bruit is heard.
Nine such patients have been encountered in the last 18
months (unpublished data).
EPIDEMIOLOGY AND ETIOLOGY
Renal artery FMD occurs in approximately 75% of
patients with FMD and is bilateral in 35% of pa-
tients.3,11,12 There is frequently a delay in diagnosis that
leads to a delay in the most appropriate treatment.
Renal artery FMD may be associated with dissection and
aneurysms (Fig 2). Few contemporary data are available on
the prevalence of renal artery aneurysms in patients with
FMD.13 In a study from1968, Kincaid et al14 reported a 9.6%
prevalence of renal artery aneurysms. A more recent study of
41 patients with renal artery FMD documented 4 patients
with renal artery aneurysms (prevalence of 9.8%).9
Extracranial cerebrovascular FMDmost commonly oc-
curs in the internal carotid artery near the level of C1-C2.
In the past it was often stated that carotid artery FMD
affected 25% to 30% of patients with FMD.15,16 However,
in the first 200 patients entered into the International
Registry for Fibromuscular Dysplasia, approximately 70%
had extracranial cerebrovascular FMD (unpublished data,
2010). Vertebral artery involvement is less common (7% to
19%); however, the prevalence of both in the general pop-
Fig 1. A 54-year-old woman underwent angiography of the carotid
arteries before surgery for a carotid body tumor.A, Left carotid artery
injection demonstrates a carotid body tumor (arrow), and medial
fibroplasia (small arrows) that were incidentally discovered. B, Out-
pouching (arrow) commonly seen in patients with medial fibroplasia
may represent a small pseudoaneurysm. (Han DK, Fishman EW,
Walkup MH, Olin JW, Marin ML, Faries PL. A rare case of familial
carotid body tumor in a patient with bilateral fibromuscular dysplasia.
J Vasc Surg 2010;52:746-50.)ulation is not known.17,18 oThere is an increased prevalence of intracranial aneurysms in
atients with extracranial cerebrovascular FMD compared with
he general population. In ameta-analysis of 18 studies involving
15 patients with carotid or vertebral artery FMD, the overall
revalence of intracranial aneurysms was 22%. However, when
atients presenting with subarachnoid hemorrhage were ex-
luded, theprevalenceof intracranial aneurysmswasonly7.3%
.0%.19Other investigators have reported a prevalence of 22% to
1%.10,11,18,19
Althoughmany theories have been proposed, including en-
ironmental factors, such as tobacco and estrogen, as well as
enetic factors, the cause of FMD is unknown. FMD over-
helmingly affects the female sex by a 9/1 ratio.4,20 Some
nvestigators have promulgated a theory that links estrogen with
predisposition to the development of FMD.21 However, nei-
heroral contraceptivesnorpregnancyappears to increase the risk
or developing FMD.22
FMD is likely, at least in part, a genetic disorder.
ettinger and Ericson10 examined the pedigree of 37
atients and concluded that there was a dominant trait with
educed penetrance. Rushton et al23 examined 20 families
nd found that 60% of FMD cases were due to an
utosomal-dominant trait with variable penetrance and
peculated that the remaining 40% were due to acquired
utations. Subsequently, Perdu et al24 reported an 11%
ncidence of FMD among first-degree relatives of individ-
als with FMD. Until first-degree relatives of patients with
MD are formally studied in larger numbers, we will not
now the patterns of inheritance or the percentage of
atients who pass this on to their offspring.
ATHOLOGIC CLASSIFICATION OF FMD
FMD is classified into three categories related to the
athologic layer of the arterial wall that is affected—intima,
edia, and adventitia (periarterial).12,25 Medial FMD is by
ar the most common type and is further subdivided into
edial fibroplasia, perimedial fibroplasia, and medial hy-
erplasia.15,25,26 Although this classification was initially
roposed for the renal arteries, it is also applicable to other
rterial beds and has been angiographically correlated with
he disease elsewhere.3
Medial fibroplasia accounts for 80% to 90% of all types of
MD.11,20 This subtype is defined histologically by alternat-
ng areas of thinnedmedia and thickened collagen-containing
edial ridges. Multiple stenotic “webs” cause arterial stenosis
nd poststenotic dilation, often displaying the typical “string
f bead” appearance on angiography (Fig 2). The “bead”
omponent is often larger than the normal arterial lumen, and
n a subset of patients with FMD, aneurysms are present that
ay require treatment (Fig 2).9,27
Intimal fibroplasia accounts for approximately 10%
f all FMD. Intimal fibroplasia is due to a collagen
eposition within the intima complicated by an often
ragmented or duplicated internal elastic lamina.11,25
ngiography shows it is distinct from medial disease
ecause the intima often causes a focal fibrotic band-like
onstriction that results in a concentric stenosis (Fig 3)
r long tubular lesion.15,26,28
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March 2011828 Olin and SealovePerimedial fibroplasia (less numerous and smaller beads
than medial fibroplasia) is quite uncommon and usually
occurs in young girls aged between 5 and 15 who present
with hypertension and renal impairment.3
Medial hyperplasia is extremely rare and requires a
pathologic specimen for diagnosis.
Adventitial fibroplasia has an unknown frequency.
Fig 2. A, A catheter-based angiogram in a 35-year-o
demonstrated fibromuscular dysplasia of the right renal
distally (white arrows). B, Aortogram in a patient with m
branches shows a large marginal artery (arrow) indicating
There is also fibromuscular dysplasia of the celiac and su
Fig 3. A 48-year-old man presented with bilateral flank
severe stenosis (arrow) of the right renal artery character
left renal artery with dilatation of the distal main renal a
shown). (Reproduced with permission from Olin JW
dysplasia. Curr Opin Cardiol 2008;23(6):527-36.)Weiner et al29 recently reported adventitial FMD was diag- tosed by intravascular ultrasound (IVUS) imaging.29 The
ngiographic appearance looks similar to intimal disease.
LINICAL PRESENTATION AND NATURAL
ISTORY
Renal artery FMD. The most common clinical presen-
oman with new-onset of severe high blood pressure
(black arrows) and two small aneurysms (6 mm) more
fibroplasia of the middle and distal renal arteries and the
re disease or occlusion of the superior mesenteric artery.
r mesenteric artery (not shown).
and increased serum creatinine. A, There is a concentric
f intimal disease. B, There is a dissection (arrow) in the
and infarction of the upper pole of the left kidney (not
rce M. Contemporary management of fibromuscularld w
artery
edial
sevepain
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, Pieation of FMD of the renal arteries is hypertension in a young
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Volume 53, Number 3 Olin and Sealove 829woman. However, FMD can occur in both sexes and present
at any age.30 The development of noninvasive imaging such as
CTA and MRA has led to the identification of FMD in
patients being imaged for other indications.31 In these situa-
tions, the FMD is asymptomatic and often an incidental
finding (Fig 1). FMD is now commonly identified in older
patients and it is also not uncommon to see both atheroscle-
rosis and FMD in the same patient.5 Other clinical manifesta-
tions of renal artery FMD include aneurysm, dissection, or
occlusion of the renal artery. Dissection is the most common
cause of renal infarction in patients with FMD (Fig 3).
Before 1990, the average age for the diagnosis of renal
artery FMD was reported to be 39 in women and 31 in
men. More recent data, however, suggest that the typical
patient presenting with renal artery involvement is older,
has had a longer duration of hypertension, and possesses
more involvement of the renal branches.32 This in all
likelihood is due to failure to diagnose FMD when patients
aged 35 years present with hypertension.
Two angiographic studies have reported the progres-
sion rate of renal artery disease secondary to FMD. Gon-
charenko et al33 evaluated 42 patients and found that all
demonstrated progression of disease. Schreiber et al34 eval-
uated 66 patients with medial fibroplasia and reported
progression in 33%, with only 2 patients demonstrating
worsening renal function and no lesion progressing to
occlusion. Both of these studies have significant methodo-
logic problems that cast doubt on these conclusions. The
only way to determine whether progression has occurred is
to observe new lesions where lesions did not exist in the
past. It is impossible to assess whether a given lesion has
more stenosis because the degree of stenosis cannot be
accurately gauged on arteriography or any other imaging
modality.
Medial fibroplasia may be present with normal blood
pressure or may present with difficult to control hyperten-
sion. There is rarely renal dysfunction with medial fibropla-
sia unless a dissection occurs. Intimal and perimedial fibro-
plasia may be associated with renal dysfunction, dissection,
and progression to occlusion.4
Extracranial cerebrovascular FMD. Carotid FMD is
most frequently located in the middle and distal part of the
internal carotid arteries and is usually bilateral (Fig
4).3,10,18 The vertebral arteries may also be involved. Ca-
rotid or vertebral artery FMD may be asymptomatic and
only discovered when a cervical bruit is heard or when
imaging is performed for another reason (Fig 1).4 In the
Mayo Clinic experience, none of the 27 asymptomatic
individuals incidentally diagnosed with carotid artery FMD
had neurologic symptoms during a 6.5-year follow-up.35
There are a myriad of nonspecific symptoms or signs
that frequently occur in patients with carotid or vertebral
artery FMD, such as dizziness, headache, altered menta-
tion, pulsatile tinnitus, neck pain, headache, wooziness,
and a swishing (swooshing, whooshing) sound in the ears.
More focal and specific neurologic signs and symptoms that
may occur include transient ischemic attack (TIA), cerebral
infarction, subarachnoid hemorrhage, syncope, Horner tyndrome, and cranial nerve palsies.10,18,36 Symptoms may
e related to one or more of the following mechanisms: (1)
evere stenosis producing hypoperfusion, (2) embolization,
3) thrombosis, (4) dissection,37 or (5) aneurysm rup-
ure.15
Other arterial beds. FMD has been reported to affect
ig 4. A, Typical medial fibroplasia of the right internal carotid
rtery. Note the “beading” is located in the middle and distal
ortion of the internal carotid artery, whereas atherosclerosis oc-
urs at the origin of the internal carotid artery. B, This 51-year-old
atient demonstrates severe tortuosity of the left internal carotid
rtery. She has medial fibroplasia of the renal arteries and an
ccluded right internal carotid artery from dissection.
ig 5. Medial fibroplasia of the external iliac arteries in a patient
ho presented with claudication. (Photograph courtesy of J. Mi-
hael Bacharach, MD.)he celiac, superior and inferior mesenteric (Fig 2, B),
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the viscera, FMD usually involves more than one vessel.
Although typically asymptomatic, mesenteric ischemia can
occur but rarely results in infarction due to extensive col-
lateralization.
Epicardial coronary artery involvement has been infre-
quently reported. Coronary FMD typically appears as a
well-demarcated, long, smooth lesion in the distal portion
of the artery. There is an abrupt transition from an angio-
graphically normal coronary artery to the abnormal area.38
Rarely, the “string of beads” appearance will occur in the
coronary arteries.
DIAGNOSTIC EVALUATION
Renal artery. Catheter-based angiography remains
the most accurate imaging technique to diagnose and
evaluate FMD. It can visualize the main renal arteries as
well as the smaller branch vessels. In fact, catheter-based
Table I. Common misconceptions regarding fibromuscula
Misconception
All coronary, carotid, and renal artery disease
is due to atherosclerosis
● FMD can c
● Most patie
risk factors
● Whereas at
FMD occu
The severity of medial fibroplasia (beading)
can accurately be ascertained by visual
inspection of the angiogram
● There is no
of an arter
● IVUS or m
arteries be
● As many as
after angio
imaging
Duplex ultrasound velocities predict degree of
carotid or renal FMD severity, or both
● The degree
● Contrary t
disease, no
● Rather tha
stenosis an
different fr
● On ultraso
increased v
distal rena
a much mo
70%) to an
Patients with renal or carotid artery
fibromuscular dysplasia undergoing
intervention should receive a stent
● There is no
circumstan
● Angioplast
normalize
● FMD occu
in the rena
complex
● The only in
result with
The most common presentation for carotid
FMD is transient ischemic attack or stroke
● Although T
presentatio
another re
● Nonspecifi
swishing (
FMD, Fibromuscular dysplasia; IVUS, intravascular ultrasound imaging;
transient ischemic attack.
aIf the presence of “beading” is demonstrated on ultrasound imaging (B-moangiography is the only imaging modality that can accu- uately identify the changes of FMD, aneurysm formation,
nd dissection in the branch vessels.39 In addition, cath-
ter-based angiography has an advantage in that a pres-
ure wire and IVUS imaging can be used to help deter-
ine the hemodynamic significance of a lesion.40-42
owda et al42 evaluated 20 consecutive patients with
uspected renal artery stenosis with DUS imaging, renal
ngiography, and IVUS imaging. On IVUS imaging,
ccentric ridges, fluttering membranes, or spiraling folds
ere present in areas where DUS and angiography dem-
nstrated abnormalities (8 patients). However, similar
efects were detected by IVUS imaging when angiogra-
hy was borderline (7 patients) or normal (5 patients).42
lthough catheter-based angiography has been consid-
red the gold standard for the diagnosis of FMD, it is
mportant to not just rely on visual inspection of the
ngiogram, because the stenosis can be subtle and only
etected with the measurement of pressure gradient or
splasia
Fact
renal, visceral, cerebrovascular, extremity, and coronary disease
e young or middle-age females, with few or no atherosclerotic
clerosis occurs at the origin or proximal portion of the vessel,
the mid and distal part of the artery
rate way to determine the degree of stenosis by visual inspection
m or other imaging studies
ement of pressure gradient should be obtained in the renal
nd after angioplasty in patients with FMD
third of patients have no demonstrated angiographic stenosis
yet have residual stenosis by pressure gradient or IVUS
stenosis” cannot be determined by Doppler velocity shift
Doppler assessment in atherosclerotic carotid or renal artery
nostic velocity criteria exist for cerebrovascular or renal FMD
area of stenosis in atherosclerosis, there are multiple areas of
tation in FMD, making the flow characteristics completely
atients with atherosclerosis
eports, we recommend a statement such as: “there is an
ty (PSV 450 cm/s), turbulence and tortuosity in the mid and
arotid) artery consistent with fibromuscular dysplasia,”a which is
curate statement than assigning a degree of stenosis (ie, 50%-
y
cation for stent placement in fibromuscular dysplasia under most
e is all that is needed to resolve the pressure gradient and
ppearance on IVUS
the mid-to-distal portion of the blood vessel; therefore, a stent
ry in which restenosis occurs will make surgical repair more
ions for stent implantation are failure to achieve a desirable
alone (rare) or dissection during the procedure
nd stroke can occur with carotid FMD, the most common
e asymptomatic and detected incidentally via imaging for
and cervical bruit
ptoms, such as headaches, dizziness, light-headed, audible
ooshing) sound in the ear
eak systolic velocity; PTA, percutaneous transluminal angioplasty; TIA,
lor Doppler, or power angiography), it should be noted in the conclusions.r dy
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diagnosis of renal artery FMD. Neither imaging modality
has good enough resolution to identify branch vessel dis-
ease.39 Both techniques can accurately identify aneu-
rysms.31,43,44
DUS is accurate in the diagnosis of atherosclerotic renal
artery stenosis and is valuable as a surveillance modality
after endovascular intervention.45 Although no large-scale
studies have compared DUS imaging with angiography for
patients with FMD, smaller reports have shown accuracy in
patients with FMD.46,47 The typical string of beads may
occasionally be seen onDUS imaging, but a more common
finding is turbulence, tortuosity, and a velocity shift in the
middle and distal arteries. It is important to visualize the
middle and distal renal arteries using an oblique, subcostal,
or flank approach in addition to an anterior approach.
Differential diagnosis
Atherosclerosis. FMD can be distinguished from ath-
erosclerotic disease due to the younger age and lack of
traditional atherosclerotic risk factors in some patients. In
addition, atherosclerosis occurs at the ostium or proximal
portion of the renal and carotid arteries, whereas FMD
occurs in the middle or distal portion of these arteries.
Because FMD is now being recognized in elderly persons, it
is not uncommon to encounter patients with both athero-
sclerosis and FMD.5,48-50
Vasculitis. FMD is a noninflammatory process,
whereas there is marked inflammation of the blood vessel in
vasculitis. Measurements of acute-phase reactants, such as
erythrocyte sedimentation rate and C-reactive protein, are
usually within normal reference ranges in FMDunless there
is infarction of the kidney or bowel. FMDmay be confused
with a vasculitis because it can occur in multiple vascular
territories and cause accelerated hypertension, kidney im-
pairment, TIA, stroke, and abnormalities such as stenosis,
aneurysm, or dissection.
Segmental arterial mediolysis. Segmental arterial
mediolysis is a poorly understood condition characterized
by spontaneous dissection(s), occlusion, or aneurysm for-
mation, or both, and is often difficult to differentiate from
FMD. It is unclear whether segmental arterial mediolysis is
a distinct vascular abnormality or a subtype of FMD.51-53
Histopathologic findings include mediolysis, which be-
gins in the outer media as a result of vacuolization. There is
separation of the media from adventitia that may result in
dissection, and arterial gaps that result in loss of intima and
media and in subsequent repair, which can result in an
appearance resembling FMD. Unlike vasculitis, there is no
inflammation or fibrinoid necrosis.51
A typical presentation may include severe abdominal or
flank pain due to infarction of the visceral organs. In a
review of 24 published cases, the distribution of visceral
involvement was as follows: celiac artery or branches (50%),
superior mesenteric artery or branches (29%), inferior mes-
enteric artery or branches (9%), and renal arteries (12%).51There is no sex predilection, and segmental arterial me- fiolysis often presents in the fourth to the eighth
ecade.52,54
Other associated diseases. An association has been
oted of FMD with other arterial diseases such as Marfan
yndrome,55 Takayasu arteritis,56,57 neurofibromatosis
ype I,58-60 and Ehlers-Danlos syndrome type IV (vascular
ype).61
There is an interesting finding of severe tortuosity in
he distal carotid arteries in patients with FMD (Fig 4). This
ay occur in the absence of other findings such beading.15
he cause of this tortuosity is not known; however, tortu-
sity of the carotid arteries occurs frequently in patients
ith typical renal artery FMD (Fig 4). Further study is
equired to determine if this type of ultrasound or angio-
raphic picture represents another manifestation of FMD.
ANAGEMENT
Renal artery FMD. The primary goal in treating pa-
ients with renal artery FMD is the control of blood pres-
ure to prevent the sequelae of long-standing poorly con-
rolled hypertension.62 In patients in whom the high blood
ressure is newly diagnosed and secondary to renal artery
MD, the initial treatment may be percutaneous translu-
inal balloon angioplasty (PTA).4,63 The chance of cure
normal blood pressure on no antihypertensive medica-
ions) is the highest when the patient is young, the duration
f hypertension is short,32,64 and the gradient is completely
bliterated at the time of angioplasty40,41,63,65 (Table I).
For patients in whom FMD was not diagnosed at the
nset of high blood pressure and the hypertension was
resent for more than several years, antihypertensive med-
cations should be continued as long as the hypertension is
ell controlled and the patient does not experience unde-
irable side effects from the medication. These patients
hould be monitored clinically every 6 months with assess-
ent of blood pressure and renal function (serum creati-
ine and estimated glomerular filtration rate).66 Renal ar-
ery DUS imaging should also be obtained every 6 to 12
onths to assess renal length and cortical thickness3,67,68
If the blood pressure becomes difficult to control,
ntolerable side effects develop secondary to the medica-
ions, or the patient’s renal size or function decreases, PTA
hould then be performed. Balloon angioplasty alone is
ery effective treatment for renal artery FMD; therefore,
here is no need for stent implantation under most circum-
tances. Because FMD occurs in the middle and distal renal
rtery and its branches, if surgical revascularization is re-
uired in the future, previous stenting may make that
evascularization much more difficult. There are two indi-
ations for stenting in renal artery FMD: if the gradient
annot be obliterated with angioplasty alone29 and to treat
dissection. The primary role for surgical revascularization
s to treat aneurysms in patients in whom endovascular
herapy is not an option27,69 or if PTA fails.30
PTA has replaced surgery as the preferred treatment of
enal artery FMD.30,63 Angioplasty has a number of advan-
ages over open surgical revascularization: it can be per-
ormed with a high degree of technical and clinical success
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March 2011832 Olin and Sealovewith minimal complications; it is less invasive, has a mark-
edly shorter recovery time, is less expensive, and may be
performed as an outpatient. PTA results in blood pressure
reduction in most patients and can be used to treat every
type of lesion in the main and branch arteries (Table
II).63,70-82 In an effort to determine the rate of cure of
hypertension after angioplasty or surgery, Trinquart et al64
performed a systematic review and meta-analysis of 47
angioplasty studies (1616 patients) and 23 surgery studies
(1014 patients). Cure of hypertension, defined according
to the criteria in each study, was estimated to be 46% (95%
confidence interval, 40%-52%) after angioplasty and 58%
after surgery (95% confidence interval, 53%-62%). There
was considerable heterogeneity across studies.
Most instances of recurrence of disease after PTA are
related to inadequate angioplasty the first time. Usually a
second PTA results in cure or improvement in blood pres-
sure.63,80 It is important to measure pressure gradients
both before and after angioplasty to be certain that all of the
webs have been disrupted and the pressure gradient has
been obliterated.40,41,65 IVUS imaging may be a useful
adjunct to demonstrate not only the type of FMD in-
volved29 but also the disruption of the webs after the
intervention.40,42
It has become our practice to get a baseline DUS image
at the first office visit after angioplasty. Patients are then put
into a surveillance program of DUS imaging every 6
months to assess kidney size, velocity elevations in the
region of previous stenosis, and any changes in cortical
thickness. If restenosis develops without resultant hyper-
tension, the patient is monitored serially without reinter-
vention. If, however, hypertension recurs and there is an
area of stenosis in the renal artery, angioplasty is repeated.
All patients with renal artery FMD are empirically pre-
Table II. Results of percutaneous transluminal angioplast
hypertensiona
Study Year
Patient
No.
Technical
success rate
% Cur
Sos et al 1983 31 87 59
Baert et al 1990 22 83 58
Tegtmeyer et al 1991 66 100 39
Bonelli et al 1995 105 89 22
Jensen et al 1995 30 97 39
Davidson et al 1996 23 100 52
Klow 1998 49 98 26
Birrer et al 2002 27 100 74
Surowiec et al 2003 14 95 79
De Fraissinette et al 2003 70 94 14
Kim et al 2008 15 79 13
Davies et al 2008 29 100 72
NR, Not reported.
aModified and updated from Slovut DP, Olin JW. Current concepts: fibrom
bThe percentage shown is the total for cured and improved.
cMedian value.scribed aspirin (81 mg daily). wCerebrovascular FMD. The overall prognosis for me-
ial fibroplasia of the carotid or vertebral arteries is quite
ood.35,83,84 Patients with asymptomatic carotid or verte-
ral artery FMD should be monitored medically and pre-
cribed aspirin (81 mg daily) for primary stroke prevention.
TA is the first line of treatment for those with symptomatic
xtracranial cerebral vascular FMD.4,85-88 There is no role
or the older technique of open graduated intraluminal
ilatation.89 Surgical therapy or endovascular therapy with
tents or coils is reserved for patients with aneurysms. If the
atient experiences amaurosis fugax, TIA, or stroke, bal-
oon PTA should be performed if feasible. If a dissection
evelops during intervention, a stent should be placed.
Patients with FMD may present with a carotid or
ertebral artery dissection. Angiographic changes of FMD
re found in about 15% of patients with a spontaneous
issection of the carotid or vertebral artery.90 If a dissection
s present, anticoagulation with heparin should be started,
ollowed by warfarin. If the patient has no further TIA or
troke, the anticoagulation should be continued for 3 to 6
onths, allowing for the dissection to heal.90 However, a
tent should be placed if the patient experiences recurrent
ymptoms while on anticoagulation.90,91
There are a host of nonspecific symptoms that patients
ith FMD experience. A common symptom is an abnormal
wishing (swooshing, whooshing) sound in one or both
ars. Some of these patients may be so debilitated because
f the constant noise in their ear that they seek support and
elp with others who are similarly afflicted (http://www.
hooshers.com).
Another common and quite bothersome symptom is
eadache. Mettinger et al10,18 recognized that headaches
ere common in individuals with FMD. The pathogenesis
f headaches in patients with FMD is not known. Most
atients with renal artery fibromuscular dysplasia and
ect on blood pressure, %
Improved Unimproved
Follow-up,
mon Mean
(range)
Complication
rate %
34 7 16 (4-40) 6
21 21 26 (6-72) NR
59 2 39 (1-121) 13
63 15 43 (0-168) 11 (major)
47 14 12 (NR) 3 (major)
22 26 NR 12 (minor)
44 30 9 (1-96) 0
26 10 (NR) 7.4
21 NR 28.5
74 12 39 (1-204) 11
80 7 24 (1-60) 16
18 24c 8 (minor)
ar dysplasia. N Engl J Med 2004;350:862-71.y in p
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tory to treatment. We have now performed internal carotid
artery balloon angioplasty on four patients with severely
debilitating headaches. All patients underwent a formal
neurologic evaluation by a headache specialist to exclude
other treatable causes for the headaches. These patients
were extremely debilitated by their headaches and frus-
trated that nothing could be done to help them. All expe-
rienced complete relief of headaches after angioplasty. The
first patient treated has now been free of headache for
nearly 3 years. Clearly, this needs to be studied in a formal
manner and reserved for only the most severely debilitated
patients. Most of our patients with headaches are not
offered angioplasty because their lesions are too diffuse,
other causes of headaches (sinus, post-traumatic) are pos-
sible, or the headaches are not severely debilitating and
usual headache therapy is helpful.
A neurosurgeon should evaluate patients with carotid
or vertebral FMD and associated intracranial aneurysms to
determine if the aneurysm needs to be observed or be
treated with surgery or endovascular stent/coiling.
Patients with carotid artery FMD should be put into a
surveillance program ofDUS imaging every 6 to 12months
basis to follow the course of the disease. It is not known
how often a patient needs to be imaged for intracranial
aneurysms after the first negative MRA.
FMD in other locations. Even less information is
available about the most effective treatment for FMD in
locations other than the renal and extracranial carotid and
vertebral arteries. Patients with claudication or acute limb
ischemia can be effectively treated with angioplasty (Fig
5).92 Those with intestinal ischemia can be treated with
angioplasty or surgery.93,94 Most patients with visceral
aneurysms will require surgical treatment. Pate et al38 de-
scribed the clinical and angiographic features of coronary
artery FMD. The disease was distal in all cases, and revas-
cularization was not possible. Therefore, symptomatic pa-
tients with coronary disease should be treated medically.
Occasionally, the coronary arteries may have a moth-eaten
(beaded) appearance that could be treated with angio-
plasty.95
UNRESOLVED ISSUES
Virtually no new information about FMD has been
published in the last 40 years. Small case series and single
case reports continue to be published. In 2009, 20 single
case reports were published in patients with FMD. This
indicates that there is virtually no significant research on
pathogenesis, genetics, imaging, or treatment. This lack of
research is largely due to the perception that FMD is a rare
disease and thus no funding has been made available by the
National Institutes of Health, other funding organizations,
or industry.
A group of individuals who have FMD or who have a
close relative with FMD founded the Fibromuscular Dys-
plasia Society of America (http://www.fmdsa.org). The
mission of this nonprofit organization is to (1) increase
awareness of FMD, (2) educate health care providers about cMD so that the diagnosis will not be overlooked or
elayed and thus complications of FMD prevented, (3)
ducate patients with FMD and provide a resource for
nformation and support with others with this disease, and
4) raise money for research and education. This organiza-
ion has succeeded in all four of these goals.
The Fibromuscular Dysplasia Society of America has
unded the International Registry for Fibromuscular Dys-
lasia. This registry will provide observational data on a
arge number of patients with FMD so that we can better
nderstand the natural history of the disease, the most
ccurate method for diagnosis, and most effective treat-
ent strategy. These data will allow for the formation of
mportant questions and goals for future research. The
egistry started with seven centers in the United States (see
ppendix, online only). There are plans to add more cen-
ers this year. The ultimate goal is to raise enoughmoney so
hat genetic studies can be undertaken to better understand
he pathogenesis of the disease. Most centers working on
arious research aspects of FMD are doing so with virtually
o funding.
Many unanswered questions remain, among them:
● What is the prevalence of FMD in the community?
● What is the prevalence of FMD in asymptomatic first-
degree relatives?
● What causes FMD?
X Genetics?
X Environmental influences?
X Hormones?
● Are most patients with FMD asymptomatic?
● What is the natural history of symptomatic and asymp-
tomatic FMD?
● Why are women affected more commonly than men?
● Why do some patients develop aneurysms? Or dissec-
tion?
● Why are headaches so common in patients with ex-
tracranial cerebrovascular FMD?
● Are there genetic markers associated with FMD?
Transforming growth factor-? Collagen type III 1
(COL3A1)?
● What is the diagnostic accuracy of DUS imaging,
MRA, and CTA for carotid and renal FMD?
● What are the ultrasound criteria for renal artery and
carotid artery stenosis in patients with FMD?
● Why is there such severe arterial tortuosity in some
patients with FMD?
ONCLUSIONS
There are a large number of patients with FMDwho are
ither not diagnosed or for whom there is a significant delay
n diagnosis and thus treatment. Once patients are diag-
osed, they are often told that nothing can be done for
hem.96 Many patients with FMD do not accept this as an
nswer and often seek out information on the Internet.
isdiagnosis or a delay in diagnosis will not occur if the
ealth care provider thinks of FMD under the following
ircumstances:
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March 2011834 Olin and Sealove1. A young person with a cervical bruit; be certain the
vascular laboratory images the middle and distal internal
carotid artery
2. A patient describing a “swishing” (swooshing, whoosh-
ing) sound or pulsatile tinnitus in the ear(s)
3. Any patient (especially those aged 60 years) with a
TIA or stroke
4. Any patient with a dissection of any artery other than the
aorta
5. Onset of hypertension in individuals aged 35 or diffi-
cult to control hypertension in anyone aged 55
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